A Randomized Phase II Study of Picoplatin or Topotecan Second-Line Therapy for Subjects with Resistant or Refractore Small Cell Lung Cancer

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/05 → 9/30/10

Funding

  • NeoRx Corporation: $15,490.00